These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38431413)

  • 1. Inhibition of catechol-O-methyltransferase (COMT) by heparin oligosaccharides with specific structures.
    Chen Q; Wang Q; Bu C; An Z; Jin L; Chi L
    Carbohydr Polym; 2024 May; 332():121909. PubMed ID: 38431413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
    Hitge R; Smit S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
    de Beer AD; Legoabe LJ; Petzer A; Petzer JP
    Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Müller T
    Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
    Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
    Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase.
    de Beer J; Petzer JP; Lourens ACU; Petzer A
    Mol Divers; 2021 May; 25(2):753-762. PubMed ID: 32108308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
    Kiss LE; Soares-da-Silva P
    J Med Chem; 2014 Nov; 57(21):8692-717. PubMed ID: 25080080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive components and mechanisms of Pu-erh tea in improving levodopa metabolism in rats through COMT inhibition.
    Zhou Z; Li Y; Wang F; Zhu G; Qi S; Wang H; Ma Y; Zhu R; Zheng Y; Ge G; Wang P
    Food Funct; 2024 May; 15(10):5287-5299. PubMed ID: 38639730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catechol-O-methyltransferase and Parkinson's disease.
    Tai CH; Wu RM
    Acta Med Okayama; 2002 Feb; 56(1):1-6. PubMed ID: 11873938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
    Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
    J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
    Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
    JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
    Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
    Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the Therapeutic Potential of a Bicyclic Hydroxypyridone Compound 2-[(2,4-Dichlorophenyl)methyl]-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one as COMT Inhibitor in the Treatment of Parkinson's Disease: A Molecular Dynamic Simulation Approach.
    Subair TI; Akawa OB; Soremekun OS; Olotu FA; Soliman MES
    Chem Biodivers; 2021 Sep; 18(9):e2100204. PubMed ID: 34252268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospecting for new catechol-
    da Silva IR; Parise MR; Pereira M; da Silva RA
    J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Pharmacother; 2022 Jul; 23(10):1123-1128. PubMed ID: 35373688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.